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ABSTRACT
Background
Standard treatment for differentiated thyroid cancer is 
thyroidectomy followed in selected cases by radioio-
dine ablation (ra). Recombinant humanized thyroid-
stimulating hormone (rhtsh) is an exogenous source 
of tsh that can be administered to obviate the need 
for hormone withdrawal. In this systematic review, 
we analysed the evidence for the therapeutic use of 
rhtsh for ra preparation.
Method
A systematic review of the  medline and  embase 
databases from 1996 through January 2008 selected 
articles reporting randomized controlled trials, co-
hort studies, and retrospective studies published in 
English that compared ra using rhtsh with standard 
hormone withdrawal.
Results and Interpretation
Stimulation by rhtsh is equivalent to thyroid hormone 
withdrawal in achieving ablation while avoiding detri-
mental symptoms of hypothyroidism and significantly 
lowering the whole-body radiation dose. Furthermore, 
rhtsh may be the only option for patients who either 
cannot raise endogenous tsh or who would be at risk 
from the morbidity of hypothyroidism. Based on 
the results of validated instruments of physical and 
mental performance, there is agreement that rhtsh 
maintains a better quality of life. Studies of cost-
effectiveness found that rhtsh-prepared patients lost 
less time from work and required fewer encounters 
with health care providers.
KEY WORDS
Radioiodine ablation, thyroid cancer, recombinant hu-
manized thyroid-stimulating hormone, systematic review
1.  INTRODUCTION
Thyroid cancer is the most common of endocrine ma-
lignancy in Canada 1 and the United States 2,3, with the 
fastest-rising incidence of all cancers. The estimated 
number of new cases in Canada in 2008 was 4300, and 
the deaths attributable to thyroid cancer for 2008 were 
estimated to have been 180 1. In the United States, 
the incidence is similar 3. Because thyroid cancer is 
an indolent disease and because it can recur decades 
after initial diagnosis and definitive primary treat-
ment, people with a thyroid cancer diagnosis require 
life-long surveillance and follow-up 4.
Patients with differentiated thyroid carcinoma 
(papillary and follicular) are usually treated surgical-
ly, with near-total or total thyroidectomy, frequently 
followed by adjuvant radioiodine (131I) therapy of 
thyroid remnants 5. Traditionally, patients are pre-
pared for radioiodine ablation (ra) by the withdrawal 
of thyroid hormone replacement, rendering them 
hypothyroid. The hypothyroid state increases endog-
enous levels of thyroid-stimulating hormone (tsh), 
which stimulates the uptake of 131I in any remaining 
thyroid cells and often also in differentiated thyroid 
cancer cells 6. The induced temporary hypothyroidism 
can cause substantial morbidities such as cold intoler-
ance, peri-orbital puffiness, weight gain, constipation, 
and slow movements, negatively affecting quality of 
life (qol) 7. In addition, pre-existing multisystem dis-
orders such as cardiac, renal, and psychiatric diseases 
may be exacerbated during hypothyroidism.
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Although the withdrawal time varies, patients 
are generally off thyroid replacement hormone for 
4–6 weeks; they restart within 1 week after  ra, 
with thyroid hormone reaching normal levels within 
2 months. Some practitioners initially replace the 
T4 form of hormone with T3, which is more rapidly 
metabolized, before a short period of total hormone 
withdrawal, with the intent of shortening the duration 
of overt hypothyroidism. However, this protocol has 
been shown to offer no clear benefit 8.
Since the end of the 1990s, several major 
changes have occurred in the postsurgical manage-
ment of differentiated thyroid cancers—for example, 
  appreciation of the importance of thyroglobulin (Tg) 
assays in follow-up, a parallel appreciation of the 
relative insensitivity of follow-up 131I scans 9, and the 
concurrent development of recombinant humanized 
tsh (rhtsh).
Exogenously administered rhtsh avoids thyroid 
hormone withdrawal and was initially approved for 
use in patients undergoing periodic 131I whole-body 
scans (wbss) and stimulated Tg measurements during 
follow-up. With rhtsh, patients can remain on thyroid 
replacement, thereby avoiding the associated morbid-
ity of hypothyroidism. Administration of rhtsh has 
proved to be a safe and effective method of stimulat-
ing 131I uptake in patients being monitored for persist-
ent or recurrent thyroid cancer, while maintaining a 
euthyroid state 10,11.
In 2006, the American Thyroid Association 
(ata) published a guideline on the management of 
patients with differentiated thyroid cancer. The ata 
taskforce issued a level B recommendation for the 
use of either thyroid hormone withdrawal or rhtsh 
for radioiodine remnant ablation 12. Since then, the 
European Commission and the U.S. Food and Drug 
Directorate have both approved the use of rhtsh 
for radioiodine remnant ablation in low-risk post-
thyroidectomy patients 13,14.
The efficacy of rhtsh for diagnostic and surveil-
lance purposes has raised the question of its utility in 
the preparation of patients for 131I adjuvant therapy, 
stimulating a systematic review of the evidence for 
the use of rhtsh for this purpose. Many countries have 
already approved a role for rhtsh in therapy of se-
lected low-risk patients, but in some centres, standard 
practice still limits its use to diagnostic surveillance 
of previously treated thyroid cancer.
2.  METHODS
2.1  Literature Search Strategy
We searched the  medline [January 1996 through 
January (week 5) 2008] and embase [1996 through 
February (week 6) 2008] databases for relevant evi-
dence. The search terms used included “thyroid can-
cer,” “thyroidectomy,” “radioactive iodine ablation,” 
“thyrotropin,” and “randomized controlled trials.” 
Relevant articles were selected and reviewed by one 
reviewer, and the reference lists from those sources 
were searched for additional trials.
2.2  Inclusion Criteria
Articles were selected for inclusion in the systematic 
review if they were fully published English-language 
reports, involving human subjects, of randomized 
controlled trials (rcts), cohort studies, and retrospec-
tive studies comparing ra preparation using rhtsh with 
standard withholding of thyroid hormone therapy in 
patients with no known metastatic disease. Outcome 
measures of interest were serum tsh levels, results of 
post-therapy scans, iodine biokinetics in remnants, 
serum Tg, urinary iodine excretion, and qol.
3.  RESULTS
3.1  Literature Search
The medline search yielded 323 results, twenty-two of 
which were potentially relevant and ordered for full 
review. The embase search yielded 132 results, eight 
of which were potentially relevant and not already 
included in the  medline search. If several papers 
were published concerning the same dataset, but with 
updated results, only the most recent paper was in-
cluded. Four articles from the search were considered 
relevant for the therapeutic use of rhtsh as compared 
with thyroid hormone withdrawal.
Quality of life was reported in only one of the 
four selected therapeutic studies 15. Because qol was 
deemed to be an important outcome for the present 
review, studies evaluating rhtsh for diagnostic 
monitoring purposes that otherwise met the inclu-
sion criteria for study design and that reported on qol 
were located and reviewed as well. Consequently, 
the section reporting qol was supplemented with 
results from three other studies 11,12,16, all of which 
compared hypothyroid (hypo) and rhtsh preparation 
for the diagnostic use of 131I.
3.2  Study Characteristics
In all four studies of therapeutic use 15,17–19, 0.9 mg 
of rhtsh was administered intramuscularly on 2 
consecutive days, followed by ra either 24 15,17,19 or 
48 18 hours after the second dose of rhtsh. Patients 
in all four studies had previously undergone total or 
near-total thyroidectomy. In all of the studies, patients 
receiving rhtsh continued on thyroxine replacement 
throughout their treatment. Table i summarizes the 
studies.
3.3  Study Quality
The literature search only yielded one  rct 15 on 
the use of rhtsh therapeutically for ra preparation. 25
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Although of good quality, this study enrolled only 
63 participants over a period of 21 months in 9 study 
sites. However, it is important to note that it was this 
study that led to the approval of rhtsh by the European 
Medicines Agency. In addition, a large prospective 
trial on this topic is unlikely, given that the incidence 
of thyroid cancer is too low for a large trial to be fea-
sible in a reasonable amount of time. Furthermore, 
the favourable prognosis and protracted nature of 
thyroid cancer means that it takes many years, and 
even decades, to reach certain endpoints 4.
The cohort studies by Barbaro et al. 17 and Pacini et 
al. 18 and the retrospective review by Robbins et al. 19 
are limited by lack of randomization, making it unclear 
whether selection bias (either self-selection by patients 
or selection by physicians) affected the results of a given 
study. In addition, Barbaro et al. 17 used a historical 
control group (that is, a thyroid hormone withdrawal 
group), which is methodologically problematic.
3.4  Successful Ablation Rates and Serum Tg Levels
The rct reported by Pacini et al. 15 compared ra prep-
aration in 63 patients divided into hypo and euthyroid 
(rhtsh) arms. In this study, a 3700-MBq dose of 131I 
was used. At 8 months’ follow-up, 86% of the hypo 
group and 75% of the rhtsh group had a negative wbs 
and, as a result, were considered successfully ablated 
(p = 0.3). The rate of successful ablation was 100% in 
both groups when success was defined as no visible 
uptake or less than 0.1% 131I uptake in the thyroid 
bed. This definition was reasonable, given that low-
grade false positive results occur because of salivary 
pooling in the oropharynx during the scan. Further-
more, 86% and 83% of the hypo and rhtsh groups 
respectively had serum Tg levels below 1.0 ng/mL 
(Table ii), further indicating that both methods of ra 
preparation led to successful ablation rates.
The cohort study reported by Barbaro et al. 17 
compared hypo and rhtsh ra preparation in 93 pa-
tients. Notably, patients in the rhtsh group underwent 
thyroid hormone withdrawal for 4 days: l-T4 was 
discontinued the day before the first dose of rhtsh and 
resumed the day after the administration of a 1110-
MBq therapeutic dose of 131I. The rates of successful 
ablation were not significantly different between the 
two groups of patients (p value not reported), but at 
the 1-year follow-up, 75.6% of the hypo group and 
76.9% of the rhtsh group had a negative wbs. Serum 
Tg levels were less than 1.0 ng/mL in 78.0% of the 
hypo group and in 86.5% of the rhtsh group.
Another cohort study, reported by Pacini et al. 18, 
compared ra preparation in 162 patients. However, in 
addition to hypo and rhtsh groups, a third group was 
prepared by both thyroid hormone withdrawal and 
administration of rhtsh (hypo+rhtsh). A 1110-MBq 
dose of 131I was given to all patients in that series. At 
6–10 months’ follow-up, 84% and 78.5% of patients 
in the hypo and hypo+rhtsh groups respectively had a 
negative wbs, but only 54% (p < 0.0001 and p < 0.01) 
of those in the rhtsh group did. It is noteworthy that, 
in this study, 131I was administered 48 hours after the 
second rhtsh injection rather than the usual 24 hours, 
which may have contributed to the lower rate of suc-
cessful ablation in the rhtsh arm. However, guidelines 
published by ata 9 indicate that serum Tg is the best 
indicator for successful ablation. They recommended 
that the uptake and scan procedure be discontinued. 
Using this criterion, the successful ablation rates were 
88%, 95%, and 74.1% in the hypo, hypo+rhtsh, and 
rhtsh groups respectively, none of which are signifi-
cantly different.
Finally, Robbins et al. 19 reported retrospectively 
on a comparison of hypo and rhtsh in 87 patients. This 
study was unique among those reviewed in that the 
dosage of 131I was individually determined based on 
table ii  Rates of successful ablation and levels of serum thyroglobulin (Tg), by study
  Reference  Comparison  131I Dose  Successful ablation  Serum Tg < 1 ng/mL
      (negative wbs)  at 6–12 months’ follow-up
      (%)  (%)
Pacini et al., 2002 18  Hypothyroid  1110 MBq  84.0 (p<0.0001)a  83.3b
  Hypothyroid + rhtsh    78.5 (p<0.01)a  84.8b
  rhtsh    54.0  86.8b
Robbins et al., 2002 19  Hypothyroid  Based on dosimetryc  80.9  0.65 ng/mLd
  rhtsh    84.4  0.50 ng/mLd
Barbaro et al., 2006 17  Hypothyroid  1110 MBq  75.6  78.0
  rhtsh    76.9  86.5
Pacini et al., 2006 15  Hypothyroid  3700 MBq  86.0  86.0
  rhtsh    75.0  83.0
a Compared with rhtsh alone.
b Based on patients whose ablation was successful.
c Mean ± standard deviation dose was 4769.3 ± 2738 MBq and 4084.8 ± 2405 MBq for the hypothyroid and rhtsh groups respectively.
d Median Tg level.
wbs = whole-body scan; rhtsh = recombinant humanized thyroid-stimulating hormone.27
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dosimetry, rather than administered in a standard fixed 
dose. For both groups, the mean dose was more than 
3700 MBq. Follow-up at approximately 1 year post-
ablation demonstrated that 80.9% of hypo and 84.4% 
of rhtsh patients had a complete response, defined 
as complete ablation of all radioiodine uptake in the 
thyroid bed. In addition, the median serum Tg levels 
at this follow-up were 0.65 ng/mL and 0.5 ng/mL 
in the hypo and rhtsh groups respectively. Overall, 
no significant difference was observed between the 
groups on measures of successful ablation.
3.5  Adverse Events
Some adverse events were associated with both meth-
ods of ra preparation. Pacini et al. 15 reported mild 
and transient nausea and fatigue in some patients in 
both groups. Additionally, some patients in the rhtsh 
group experienced a loss of taste, and some patients 
in the hypo group experienced skeletal pain. Barbaro 
et al. 17 reported observing no significant side effects 
after the administration of rhtsh.
3.6  Serum TSH Levels
Mean baseline serum tsh levels in the hypo patients 
were significantly higher than those in the rhtsh 
groups 15,17–19. The administration of rhtsh led to 
substantial increases in serum tsh levels from baseline 
levels in all the studies that reported this variable. 
Serum tsh levels are considered sufficient for ra-
dioiodine therapy when they reach 25–30 mU/L 6,19. 
Table iii summarizes serum tsh levels.
3.7  Iodine Biokinetics
Baseline 24-hour 131I uptake, following administra-
tion of a tracer dose of 131I, was reported in only two 
papers. In the Pacini et al. 18 report, baseline 24-hour 
131I uptake in the hypo and hypo+rhtsh groups was 
5.8% ± 5.7% and 5.4% ± 5.7% respectively and not 
significantly different. No baseline value was reported 
for the rhtsh group. Following administration of 
rhtsh, mean 24-hour 131I uptake was 9.4% ± 9.5% in 
the hypo+rhtsh group, which was significantly higher 
than the baseline level (p < 0.0001), and 2.5% ± 4.3% 
in the rhtsh group. The value in the rhtsh group 
was significantly lower than that in the hypo+rhtsh 
group (p < 0.0001). Robbins et al. 19 reported me-
dian baseline 24-hour 131I uptake values that were 
significantly different between the hypo and rhtsh 
groups (1.65% and 0.9% respectively, p = 0.05), but 
did not report values following the administration of 
rhtsh. Barbaro et al. 17 evaluated 24-hour 131I uptake 
in only a subset of patients after administration of 
rhtsh, but found that the hypo and rhtsh groups did 
not differ significantly (3.30% vs. 2.29%). Only two 
studies reported post-ablation 131I uptake 15,19, and 
the difference between the hypo and rhtsh groups in 
each study was not statistically significant. Table iv 
summarizes 24-hour 131I uptake.
Other measures of iodine biokinetics such as 
mean effective half-life and mean residence time 
in the remnants are reported only in the paper by 
Hanscheid et al. 20. The effective half-life is a combi-
nation of biologic excretion and physical decay; it is 
the time after which the 131I activity drops by 50%. The 
effective half-life in remnant tissue was significantly 
shorter (p = 0.01) in the hypo group than in the euthy-
roid group (48 ± 52.6 hours vs. 67.6 ± 48.8 hours). 
Mean residence times in the hypo and rhtsh groups 
were 1.4 ± 1.5 hours and 0.9 ± 1.3 hours respectively 
(not significantly different). Finally, mean dose to 
the blood was significantly higher in the hypo group 
than in the rhtsh group (0.167 mGy vs. 0.109 mGy, 
p < 0.0001). Overall, as compared with patients in 
table iii  Serum levels of thyroid-stimulating hormone (tsh)
  Reference  Comparison  Mean serum tsh ± standard deviation (mU/L)
    Baseline  24 Hours
      after rhtsh
Pacini et al., 2002 18  Hypothyroid  63.2±19.6a  na
  Hypothyroid + rhtsh  71.0±35.9a  281±97.0a
      (p<0.0001)
  rhtsh  1.30±2.5a  126±44.8a
    (p<0.0001)  (p<0.0001)
Robbins et al., 2002 19  Hypothyroid  97.5±50  na
  rhtsh  6.0±9.5  105.1±45.4
Barbaro et al., 2006 17  Hypothyroid  50±3  na
  rhtsh  0.04–0.35b  126±10
Pacini et al., 2006 15  Hypothyroid  83.0±51  na
  rhtsh  1.1±1.3  nr
a Pacini et al. (2002) 18 report serum tsh levels in microunits per millilitre, which is equivalent to milliunits per litre.
b Range reported only.
rhtsh = recombinant humanized tsh; na = not applicable; nr = not reported.28
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the hypo group, patients in the rhtsh group received 
higher doses of radiation to the remnants and a 35% 
reduction in whole-body radiation dose.
3.8  Quality of Life
Baseline qol in the retrieved studies was taken post 
cancer diagnosis or post surgery and before initiating 
a protocol for tsh elevation. All the studies reviewed 
for this outcome demonstrated that qol was worse in 
the hypo group when compared with either baseline 
values or with qol in the rhtsh group.
Pacini et al. 15 assessed qol using the Billewicz 
scale and the Medical Outcomes Study Short Form 
36 (SF-36). As compared with participants in the 
rhtsh group, participants in the hypo group scored 
higher (that is, worse) on 6 of the 14 signs and symp-
toms of hypothyroidism on the Billewicz scale (p < 
0.0001). These items included cold intolerance (50% 
vs. 21%), weight gain (60% vs. 21%), constipation 
(43% vs. 3%), slow movements (50% vs. 12%), cold 
skin (47% vs. 12%), and peri-orbital puffiness (50% 
vs. 0%). In addition, the change from baseline to 
week 4 in the euthyroid group was significantly dif-
ferent from the change observed in the hypo group 
for 5 of the 8 health-related qol domains of the 
SF-36. These domains were physical functioning 
(p < 0.016), role-physical (p < 0.018), vitality (p < 
0.0001), social functioning (p < 0.0001), and mental 
health (p < 0.002).
Schroeder et al. 12 expressly set out to assess 
and compare qol in patients undergoing preparation 
for diagnostic evaluation using tsh withdrawal and 
rhtsh. Those authors determined that, for all 14 signs 
and symptoms of hypothyroidism on the Billewicz 
scale, qol was significantly worse in the hypo group 
than in the rhtsh group (p < 0.001). Likewise, they 
found that, as compared with patients in the rhtsh 
group, patients in the hypo group reported signifi-
cantly lower qol on all 8 health-related qol domains 
on the SF-36 (p < 0.0001) and on the physical and 
mental composite scores of the SF-36 (p < 0.0001 in 
each case). Ladenson et al. 11 also found that qol was 
significantly worse in the hypo group as compared 
with the rhtsh group on all signs and symptoms of 
hypothyroidism on the Billewicz scale (p < 0.001). 
This group of researchers also assessed qol using the 
Profile of Mood States (poms) and reported that, as 
compared with the euthyroid group, the hypo group 
had significantly worse qol on all 6 states measured 
on the poms (p < 0.001). Finally, in 2002, Ladenson 16 
compared qol in hypo and rhtsh groups and found that 
the hypo group had significantly worse qol for 5 of 
the 6 states assessed on the poms and for the physical 
composite scores of the SF-36, although probability 
values were not reported in that article.
3.9  Cost Effectiveness
Three studies investigated the economic impact of 
rhtsh as compared with hormone withdrawal.
Luster et al. 21 conducted a retrospective survey. 
Of patients who were employed in salaried positions 
outside the home, 62% missed at least 4 days of work 
(median: 11 days) during their last hypothyroid epi-
sode. When outliers were removed from the data, the 
median number of days missed was still 7.5 (range: 
0–70 days). Moreover, 38% of respondents reported 
table iv  Iodine biokinetics in remnants: 24-hour 131I uptake (mean ± standard deviation)
  Reference  Comparison    24-Hour 131I uptake
    Before rhtsh  Hypothyroid or  After ablation
      after rhtsh 
Pacini et al., 2002 18  Hypothyroid  5.8±5.7  na  nr
  Hypothyroid + rhtsh  5.4±5.7  9.4±9.5  nr
      (p<0.0001)a 
  rhtsh  nr  2.5±4.3  nr
      (p<0.0001)b 
Robbins et al., 2002 19  Hypothyroid  1.65c  na  0.25c
  rhtsh  0.9c  nr  0.17c
    (p=0.05)   
Barbaro et al., 2006 17  Hypothyroid  nr  3.30±0.7d  nr
  rhtsh  nr  2.29±0.45d  nr
Pacini et al., 2006 15  Hypothyroid  nr  na  0.9±1.1e
  rhtsh  nr  nr  0.5±0.7e
a Comparison within the hypothyroid + rhtsh group, before and after rhtsh.
b Comparison between the hypothyroid + rhtsh group and the rhtsh group after rhtsh.
c Median value.
d Evaluated on a subset of patients only.
e 48-Hour 131I uptake.
rhtsh = recombinant humanized tsh; nr = not reported; na = not applicable.29
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taking additional prescription or over-the-counter 
drugs to relieve hypothyroid symptoms, and 48% re-
ported the use of a primary care physician, a specialist 
physician, or hospital services because of hypothyroid 
symptoms. In the economic model presented in the 
article, the societal cost per diagnostic wbs with prepa-
ration by thyroid hormone withdrawal exceeded by 
25% or €326 that with preparation by rhtsh 21.
Borget et al. 22 compared the frequency, duration, 
and cost of sick leave for follow-up of thyroid cancer 
in hormone-withdrawal and rhtsh patients. Active 
patients in the rhtsh arm were less likely to need sick 
leave than were those in the hypo arm (11% vs. 33%, 
p = 0.001), and they had shorter sick leaves (3.1 days 
vs. 11.2 days, p = 0.002). Indirect costs owing to 
absenteeism amounted to €1083 more per person in 
the hypo group than in the rhtsh group.
Mernagh et al. 23 conducted a cost-effectiveness 
evaluation of rhtsh compared with hormone with-
drawal and reported that the benefits of rhtsh are 
achieved with a small incremental societal cost of 
€47. That difference equates to an incremental cost-
effectiveness ratio of €950 per quality-adjusted life 
year, which is considered to be very good value for 
money, considering that new health care interventions 
are deemed cost-effective if their incremental cost-
effectiveness ratio falls below €45,000 23.
4.  DISCUSSION
There are two fundamental reasons to administer 131I 
following thyroidectomy for differentiated thyroid 
cancer—namely,
•  as adjuvant therapy to destroy the remaining nor-
mal thyroid follicular cells to facilitate follow-up 
and to ease early detection of recurrence, or
•  as therapy for disease that proved to be unresect-
able at surgery.
This review has been concerned only with the 
first of these indications. Because ablation is directed 
against residual normal thyroid cells, the specifics of 
the underlying differentiated malignancy are not rel-
evant to this discussion. Here, we compared only the 
methods of elevating tsh against the endpoint of suc-
cessful ablation; we did not address ongoing debates 
concerning other aspects of thyroid cancer care.
A systematic review of the available evidence 
on the use of rhtsh compared with thyroid hormone 
withdrawal in preparation for ra yielded four relevant 
studies consisting of one rct, two cohort studies, and 
one retrospective study. Examination of the outcomes 
of these studies with respect to achieving ablation 
revealed that the use of rhtsh for ra preparation is 
not different from thyroid hormone withdrawal. Three 
of these four studies found similar rates of negative 
wbs by both methods of preparation 15,17,19. Follow-
ing surgery and ra, tsh-stimulated serum Tg under 
either method of preparation is a sensitive indicator 
of residual thyroid tissue or the presence of cancer 
(or both). By the criteria of negative wbs and Tg, 
hypothyroid and euthyroid patients in all four stud-
ies had similar rates of successful ablation at 6–12 
months post-ablation follow-up 15,17–19.
Serum tsh levels of 25–30 mU/L are considered 
sufficiently high for radioiodine therapy 6,19. In all 
the studies reviewed, serum tsh in the hypothyroid 
patients was sufficient to ensure an adequate uptake 
of 131I. Three studies reported that serum tsh levels 
after administration of rhtsh were sufficient for the 
131I uptake needed for ra therapy. Successful abla-
tion was defined by some researchers as a 24-hour 
131I uptake in the thyroid bed of less than 1% of the 
administered dose in a follow-up scan 24. Of the two 
studies reporting that endpoint 15,19, both found 24-
hour 131I uptake to be less than 1%, with no signifi-
cant difference between patients prepared by thyroid 
withdrawal and patients prepared by rhtsh.
In two studies 18,25, a fixed 1110-MBq dose of 
131I was administered to all patients, but in a more 
recent study 15, a larger fixed 3700-MBq dose was 
used. In the Robbins et al. 19 study, the 131I adminis-
tered to each individual patient was calculated based 
on dosimetry. The mean dose in both groups in that 
study was well above 3700-MBq. The higher dose of 
131I might result in higher successful ablation rates. 
Centres continue to differ in the selection of 131I dos-
age, but these differences did not affect our review of 
the methods employed to elevate tsh.
The report by Hanscheid et al. 20 regarding other 
biokinetic measures in the patients originally studied 
by Pacini et al. 15 found that the mean radiation dose 
in the remnant was similar in the two groups, but that 
the mean blood dose, a proxy for whole-body dose, 
was significantly (30%) lower. That difference is 
attributable to the impairment of renal function that 
occurs during hypothyroidism 20.
Investigators continue to explore the limits of safe 
and effective 131I dosage. In a recent rct, Pilli et al. 26 
compared 1850-MBq and 3700-MBq doses of 131I 
after preparation by rhtsh and demonstrated the same 
rate of successful ablation (88.9%) in each arm. At the 
high end of the dose range, Tuttle et al. 27 conducted 
a retrospective analysis of 535 dosimetry studies in 
hypo patients and concluded that the fixed empiric 
dosing strategy of 5550–9250 MBq used by many 
centres frequently results in older patients (70 years 
of age and older) being exposed to a blood radia-
tion dose of more than 200 cGy, the recommended 
safety limit. A lower body radiation dose achieved 
through preparation with rhtsh may lower the risk 
of radiation-induced second cancers 28, although this 
effect has not been confirmed in trials. Collectively, 
the foregoing studies make a compelling argument in 
favour of rhtsh preparation for ra ablation.
The studies measuring qol 11,12,15,16 consistently 
reported improved qol in terms of both hypothyroid 
symptoms and general quality of life for rhtsh as 30
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compared with hypo on the Billewicz, SF-36, and 
poms instruments.
The direct cost of ra by either protocol is identi-
cal, except that rhtsh costs $1500 in Canada. The pre-
viously cited European studies of cost-effectiveness 
showed that rhtsh-treated patients had a better qol 
and, as a result of improved performance capacity, 
were returning earlier to work and making less use of 
the health care system. These benefits likely translate 
to the Canadian environment as well.
Finally, some patients cannot achieve satisfac-
tory levels of endogenous tsh with thyroid hormone 
withdrawal, and others are contraindicated for hy-
pothyroidism because of other medical disorders. 
Studies in these populations demonstrated that the 
use of rhtsh is effective 29,30.
Prospective rcts investigating the therapeutic use 
of rhtsh are limited in number. Other prospective and 
retrospective studies have the potential biases inherent 
in nonrandomized data. However, it is compelling that 
all the studies retrieved for this review demonstrated 
the consistent efficacy of rhtsh as a preparation 
method for ra of thyroid remnants.
The indolence of differentiated thyroid cancers 
complicates the understanding of long-term outcomes 
following ablation by whatever protocol. Two recent 
reports considered the long-term efficacy of abla-
tion therapy given with rhtsh stimulation: one was a 
follow-up of the Pacini et al. series at 3 years 31, and 
the other was a retrospective review of outcomes in 
176 patients at 3–8.5 years later 32. In both cases, no 
differences were found.
5.  CONCLUSIONS
Based on current evidence, the efficacy of rhtsh 
for ra preparation following total or near-total thy-
roidectomy in patients with papillary or follicular 
thyroid cancer is equivalent to the traditional method 
of thyroid hormone withdrawal. In selected patients 
who cannot tolerate prolonged hypothyroidism or in 
patients who cannot achieve satisfactory elevation of 
endogenous tsh by means of thyroid hormone with-
drawal, rhtsh may be the only option for radioabla-
tion. Recombinant humanized tsh allows patients to 
remain euthyroid, thereby avoiding the morbidities 
of hypothyroidism and resulting in better qol than is 
seen with thyroid hormone withdrawal.
6.  CONFLICT OF INTEREST DISCLOSURE
JY and RC declare no potential conflicts of interest. 
AD declares research support from Genzyme Cor-
poration for the development and maintenance of a 
thyroid cancer database. This author also received 
honoraria from Genzyme exceeding $5000 annually, 
all of which have been signed over to the research 
fund of the Department of Nuclear Medicine at the 
London Health Sciences Centre.
7.  REFERENCES
  1.  Canadian Cancer Society, National Cancer Institute of Canada. 
Canadian Cancer Statistics 2008. Toronto, Canada: Canadian 
Cancer Society; 2008.
  2.  Jemal A, Siegal R, Ward E, et al. Cancer statistics, 2006. CA 
Cancer J Clin 2006;56:106–30.
  3.  American Cancer Society. Cancer Facts and Figures 2008. 
Atlanta: American Cancer Society; 2008.
  4.  Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical 
and medical therapy on papillary and follicular thyroid cancer. 
Am J Med 1994;97:418–28.
  5.  Schlumberger MJ. Papillary and follicular thyroid carcinoma. 
N Engl J Med 1998;338:297–306.
  6.  Robbins RJ, Schlumberger MJ. The evolving role of 131I for 
the treatment of differentiated thyroid carcinoma. J Nucl Med 
2005;46(suppl 1):28S–37S.
  7.  Dow KH, Ferrell BR, Anello C. Quality-of-life changes in pa-
tients with thyroid cancer after withdrawal of thyroid hormone 
therapy. Thyroid 1997;7:613–19.
  8.  Leboeuf R, Perron P, Carpentier AC, Verreault J, Langlois MF. 
l-T3 preparation for whole body scintigraphy: a randomized 
controlled trial. Clin Endocrinol (Oxf) 2007;67:839–44.
  9.  Cooper DS, Doherty GM, Haugen BR, et al. Management 
guidelines for patients with thyroid nodules and differentiated 
thyroid cancer. Thyroid 2006;16:109–41.
  10.  Haugen BR, Pacini F, Reiners C, et al. A comparison of recom-
binant human thyrotropin and thyroid hormone withdrawal for 
the detection of thyroid remnant or cancer. J Clin Endocrinol 
Metab 1999;84:3877–85.
  11.  Ladenson PW, Braverman LE, Mazzaferri EL, et al. Com-
parison of administration of recombinant human thyrotropin 
with withdrawal of thyroid hormone for radioactive iodine 
scanning in patients with thyroid carcinoma. N Engl J Med 
1997;337:888–96.
  12.  Schroeder PR, Haugen BR, Pacini F, et al. A comparison 
of short-term changes in health-related quality of life in 
thyroid carcinoma patients undergoing diagnostic evalua-
tion with recombinant human thyrotropin compared with 
thyroid hormone withdrawal. J Clin Endocrinol Metab 
2006;91:878–84.
  13.  European Medicines Agency (emea). European Public Assess-
ment Report (EPAR): Thyrogen. EPAR Summary for the Public. 
London, U.K.: emea; 2007. [Available online at: www.emea.
europa.eu/humandocs/PDFs/EPAR/Thyrogen/244999en1.pdf; 
cited July 30, 2009]
  14.  Medical News Today. Genzyme announces FDA approval 
of Thyrogen for use in thyroid cancer ablation [Web article]. 
Bexhill-on-Sea, U.K.: MediLexicon International; 2007. 
[Available at: www.medicalnewstoday.com/articles/92042.
php; cited April 6, 2009]
  15.  Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine 
ablation of thyroid remnants after preparation with recombinant 
human thyrotropin in differentiated thyroid carcinoma: results 
of an international, randomized, controlled study. J Clin En-
docrinol Metab 2006;91:926–32.
  16.  Ladenson PW. Recombinant thyrotropin for detection of 
recurrent thyroid cancer. Trans Am Clin Climatol Assoc 
2002;113:21–30.31
Current OnCOlOgy—VOlume 16, number 5
YOO et al.
  17.  Barbaro D, Boni G, Meucci G, et al. Recombinant human 
thyroid-stimulating hormone is effective for radioiodine abla-
tion of post-surgical thyroid remnants. Nucl Med Commun 
2006;27:627–32.
  18.  Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid 
residues with 30 mCi 131I: a comparison in thyroid cancer pa-
tients prepared with recombinant human tsh or thyroid hormone 
withdrawal. J Clin Endocrinol Metab 2002;87:4063–8.
  19.  Robbins RJ, Larson SM, Sinha N, et al. A retrospective review 
of the effectiveness of recombinant human tsh as a prepara-
tion for radioiodine thyroid remnant ablation. J Nucl Med 
2002;43:1482–8.
  20.  Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinet-
ics and dosimetry in radioiodine therapy of thyroid cancer: 
procedures and results of a prospective international controlled 
study of ablation after rhtsh or hormone withdrawal. J Nucl 
Med 2006;47:648–54.
  21.  Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone 
withdrawal in patients with differentiated thyroid carcinoma: a 
one hundred thirty–patient pilot survey on consequences of hy-
pothyroidism and a pharmacoeconomic comparison to recom-
binant thyrotropin administration. Thyroid 2005;15:1147–55.
  22.  Borget I, Corone C, Nocaudie M, et al. Sick leave for follow-
up control in thyroid cancer patients: comparison between 
stimulation with Thyrogen and thyroid hormone withdrawal. 
Eur J Endocrinol 2007;156:531–8.
  23.  Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, 
Weston AR. Cost-effectiveness of using recombinant human 
tsh prior to radioiodine ablation for thyroid cancer, compared 
with treating patients in a hypothyroid state: the German per-
spective. Eur J Endocrinol 2006;155:405–14.
  24.  Vermiglio F, Violi MA, Finocchiaro MD, et al. Short-term 
effectiveness of low-dose radioiodine ablative treatment of 
thyroid remnants after thyroidectomy for differentiated thyroid 
cancer. Thyroid 1999;9:387–91.
  25.  Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 
30 mCi after recombinant human thyrotropin stimulation in 
thyroid cancer: effectiveness for postsurgical remnants ablation 
and possible role of iodine content in l-thyroxine in the outcome 
of ablation. J Clin Endocrinol Metab 2003;88:4110–15.
  26.  Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 
(50 mCi) and 3700 MBq (100 mCi) 131-iodine administered 
doses for recombinant thyrotropin–stimulated postoperative 
thyroid remnant ablation in differentiated thyroid cancer. J 
Clin Endocrinol Metab 2007;92:3542–6.
  27.  Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive 
iodine dosing regimens frequently exceed maximum tolerated 
activity levels in elderly patients with thyroid cancer. J Nucl 
Med 2006;47:1587–91.
  28.  Rubino C, de Vathaire F, Dottorini ME, et al. Second pri-
mary malignancies in thyroid cancer patients. Br J Cancer 
2003;89:1638–44.
  29.  Robbins RJ, Driedger A, Magner J, on behalf of the U.S. and 
Canadian Thyrogen Compassionate Use Program Investigator 
Group. Recombinant human thyrotropin–assisted radioiodine 
therapy for patients with metastatic thyroid cancer who could 
not elevate endogenous thyrotropin or be withdrawn from 
thyroxine. Thyroid 2006;16:1121–30.
  30.  Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson 
SM. Compassionate use of recombinant human thyrotropin 
to facilitate radioiodine therapy: case report and review of 
literature. Endocr Pract 2000;6:460–4.
  31.  Elisei R, Corone C, Driedger A, et al. Follow-up of differ-
entiated thyroid cancer patients who underwent radioiodine 
ablation of postsurgical thyroid remnants after recombinant 
human thyrotropin or thyroid hormone withdrawal [abstract]. 
Eur J Nucl Med 2007;34(suppl 2):405.
  32.  Rachinsky I, Driedger A, Warnock L. rh-tsh is as effec-
tive as thyroid hormone withdrawal protocol for radioio-
dine ablation. Long term followup [abstract]. J Nucl Med 
2008;49(suppl 1):7P.
Correspondence to: John Yoo, Department of 
Otolaryngology, Schulich School of Medicine and 
Dentistry, University of Western Ontario, 800 Com-
missioners Road East, London, Ontario  N6A 5W9.
E-mail: john.yoo@lhsc.on.ca
* Department of Otolaryngology, Schulich School 
of Medicine and Dentistry, University of Western 
Ontario, London, ON.
† Cancer Care Ontario, Program in Evidence-Based 
Care and Department of Clinical Epidemiology 
and Biostatistics, McMaster University, Hamilton, 
ON.
‡ Division of Nuclear Medicine, Schulich School 
of Medicine and Dentistry, University of Western 
Ontario, London, ON.